Sign In
Buy MGTX
$12.52
+0.310 (+2.54%)
At Close: Jul 21, 2026
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
10:55am, Wednesday, 15'th Jul 2026
The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
03:19pm, Sunday, 12'th Jul 2026
Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity ho
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
10:51am, Wednesday, 08'th Jul 2026
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered in
MeiraGTx: The Market Is Missing The Manufacturing Pivot
08:27am, Monday, 29'th Jun 2026
MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies,
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
04:32pm, Friday, 05'th Jun 2026
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:30am, Friday, 15'th May 2026
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 14'th May 2026
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Com
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
10:10am, Thursday, 14'th May 2026
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
08:00am, Thursday, 14'th May 2026
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostom
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
11:00am, Tuesday, 05'th May 2026
MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
07:55am, Monday, 20'th Apr 2026
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade
01:01am, Saturday, 18'th Apr 2026
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) shares saw unusually-strong trading volume on Friday after Royal Bank Of Canada raised their price target on the stock from $16.00 to $24.00. Roy
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
10:16am, Thursday, 16'th Apr 2026
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
